Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: A retrospective study using Clinical Practice Research Datalink

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 5, 2015, Pages 955-963

  Edson Heredia, E ^a   Zhu, B ^a   Lefevre, C ^a   Wang, M ^b   Barrett, A ^a   Bushe, C J ^a   Cox, A ^a   Wu, J J ^c   Maeda Chubachi, T ^a  

^a ELI LILLY AND COMPANY   (United States)

^b EVIDERA   (United Kingdom)

^c KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; OPIATE; SALAZOSULFAPYRIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SKIN CANCER; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HYPERLIPIDEMIAS; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SPONDYLITIS, ANKYLOSING; YOUNG ADULT;

ADULT; AGED; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SPONDYLITIS, ANKYLOSING; YOUNG ADULT;

EID: 84928331733     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12742     Document Type: Article

References (32)

1. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ,. Prevalence and treatment of psoriasis in the united kingdom: a population-based study. Arch Dermatol 2005; 141: 1537-1541.
2. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P,. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl. 2): ii14-ii17.
3. Krueger GC,. Clinical features of psoriatic arthritis. Am J Manag Care 2002; 8 (6 Suppl.): S160-S170.
4. Brockbank J, Gladman D,. Diagnosis and management of psoriatic arthritis. Drugs 2002; 62: 2447-2457.
5. Gulliver W,. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008; 159 (Suppl. 2): 2-9.
6. Gelfand JM, Troxel AB, Lewis JD, et al.,. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-1499.
7. Gisondi P, Tessari G, Conti A, et al.,. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
8. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M,. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-328.
9. Gerdes S, Mrowietz U,. Impact of comorbidities on the management of psoriasis. Curr Probl Dermatol 2009; 38: 21-36.
10. Menter A, Gottlieb A, Feldman SR, et al.,. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
11. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB,. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
12. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM,. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891-895.
13. Griffiths CE, Clark CM, Chalmers RJ, Li Wan Po A, Williams HC,. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 1-125.
14. Griffiths CE, Dubertret L, Ellis CL, et al.,. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004; 150 (Suppl. 67): 11-23.
15. Stern RS, Lunder EJ,. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998; 134: 1582-1585.
16. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman H, Bala MV,. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33: 2167-2172.
17. Kimhi O, Caspi D, Bornstein NM, et al.,. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007; 36: 203-209.
18. Gladman DD,. Psoriatic arthritis. Dermatol Ther 2009; 22: 40-55.
19. Gladman DD, Farewell VT, Wong K, Husted J,. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998; 41: 1103-1110.
20. Wong K, Gladman DD, Husted J, Long JA, Farewell VT,. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40: 1868-1872.
21. Langham S, Langham J, Goertz HP, Ratcliffe M,. Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: a systematic and critical review. BMC Med Res Methodol 2011; 11: 32.
22. Jick H, Jick SS, Derby LE,. Validation of information recorded on general practitioner based computerised data resource in the united kingdom. BMJ 1991; 302: 766-768.
23. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM,. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J 2010; 31: 1000-1006.
24. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM,. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
25. Griffiths CE, Barker JN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
26. Balci DD, Balci A, Karazincir S, et al.,. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereo l 2009; 23: 1-6.
27. Ludwig RJ, Herzog C, Rostock A, et al.,. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-276.
28. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG,. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700-703.
29. Wu JJ, Nguyen TU, Poon Ms KT, Herrinton LJ,. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol 2012; 67: 924-930.
30. Yeung H, Takeshita J, Mehta NN, et al.,. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 2013; 149: 1173-1179.
31. Husted JA, Thavaneswaran A, Chandran V, Eder L,. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison. Arthritis Care Res (Hoboken) 2011; 63: 1729-1735.
32. European Commission. Indicators for Monitoring Musculoskeletal Problems and Conditions. Musculoskeletal Problems and Functional Limitation. University Of Oslo, Oslo, Norway, 2003.